Case Report: Combined Small Cell Lung Carcinoma With Pulmonary Adenocarcinoma

Shen, Cheng; Che, Guowei

doi:10.3389/fsurg.2022.830849

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reviews and case reports have discussed the development of C-SCLC [20][21][22]. It is hypothesized that any lung epithelial cell (i.e., neuroendocrine, basal, or totipotent epithelial cell) could differentiate de novo or as the disease progresses under treatment pressure.…”

Section: Combined Histology Tumours and Sclc Transformationmentioning

confidence: 99%

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer

Melosky¹,

Leighl

Dawe

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in radiation therapy, progress in the systemic treatment of SCLC had been stagnant for over three decades despite multiple attempts to develop alternative therapeutic options that could improve responses and survival. Recent promising developments in first-line and subsequent therapeutic approaches prompted a Canadian Expert Panel to convene to review evidence, discuss practice patterns, and reach a consensus on the treatment of extensive-stage SCLC (ES-SCLC). The literature search included guidelines, systematic reviews, and randomized controlled trials. Regular meetings were held from September 2022 to March 2023 to discuss the available evidence to propose and agree upon specific recommendations. The panel addressed biomarkers and histological features that distinguish SCLC from non-SCLC and other neuroendocrine tumours. Evidence for initial and subsequent systemic therapies was reviewed with consideration for patient performance status, comorbidities, and the involvement and function of other organs. The resulting consensus recommendations herein will help clarify evidence-based management of ES-SCLC in routine practice, help clinician decision-making, and facilitate the best patient outcomes.

show abstract

Section: Combined Histology Tumours and Sclc Transformationmentioning

confidence: 99%